239 related articles for article (PubMed ID: 32148190)
1. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
Lancelotta RL; Davis AK
J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
[TBL] [Abstract][Full Text] [Related]
2. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
3. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
[TBL] [Abstract][Full Text] [Related]
4. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR
Front Psychol; 2018; 9():2459. PubMed ID: 30574112
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
[TBL] [Abstract][Full Text] [Related]
6. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
7. Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon's predictors and its emotional valence.
Ortiz Bernal AM; Raison CL; Lancelotta RL; Davis AK
Front Psychiatry; 2022; 13():1049643. PubMed ID: 36523876
[TBL] [Abstract][Full Text] [Related]
8. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
[TBL] [Abstract][Full Text] [Related]
9. 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study.
Ragnhildstveit A; Khan R; Seli P; Bass LC; August RJ; Kaiyo M; Barr N; Jackson LK; Gaffrey MS; Barsuglia JP; Averill LA
Front Psychiatry; 2023; 14():1271152. PubMed ID: 38076677
[TBL] [Abstract][Full Text] [Related]
10. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
11. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
[TBL] [Abstract][Full Text] [Related]
12. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
13. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
14. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
[TBL] [Abstract][Full Text] [Related]
15. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
Tap SC
Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
[TBL] [Abstract][Full Text] [Related]
16. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
17. Trends in DMT and other tryptamine use among young adults in the United States.
Palamar JJ; Le A
Am J Addict; 2018 Oct; 27(7):578-585. PubMed ID: 30260086
[TBL] [Abstract][Full Text] [Related]
18. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
19. Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".
Al-Imam A; Motyka MA; Hoffmann B; Magowska A; Michalak M
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375778
[TBL] [Abstract][Full Text] [Related]
20. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
